Newscope Capital Corporation

CSE: PHRM

Company Logo

Company Overview

Newscope Capital Corporation (CSE: PHRM), doing business through its wholly-owned subisidiary, Pharmather Inc., is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals.

The company repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Its team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. 

The company's goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, traumatic brain injury and stroke.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

$0.00

Diluted EPS (ttm)

Management Team

Mr. Fabio Chianelli
CEO & Director

Mr. Carmelo Marrelli A.C.I.S., B.Com., C.A., C.P.A., CPA, B.Comm., CA
Chief Financial Officer

Andrew Todd
Corp. Sec.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
47,326 (0%)

Insider Ownership
0%